Navigation Links
GlaxoSmithKline CEO Interviewed On Half-Year and Q2 Results
Date:7/21/2010

LONDON, July 21, 2010 /PRNewswire-FirstCall/ -- In an interview with financial broadcaster http://www.cantos.com, GlaxoSmithKline CEO Andrew Witty says one-offs held back sales growth in Q2 but highlights the strong underlying performance of Emerging Markets, Consumer and Vaccines.

The Pharma boss also points to "an unprecedented" five new drugs in late stage trials as a sign of the successful restructuring of the group.

Mr Witty tackles the ongoing Avandia controversy and the recent GBP1.6bn payout, saying "it was actually in the best interest of the company's shareholders."

The interview and transcript are available now on http://www.cantos.com/company/GlaxoSmithKline.

Cantos.com, the online financial broadcaster, features in-depth interviews, documentaries and webcasts with senior company executives. If you would like to contact us, please email amanda.alexander@cantos.com or phone +44-207-936-1352.


'/>"/>
SOURCE GlaxoSmithKline
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
2. GlaxoSmithKline Accelerates Review of Exelixis XL880
3. New Data Show That GlaxoSmithKlines Rotarix(R) Could Be Given With Other Routine Infant Vaccines in the U.S.
4. Coley Pharmaceutical Group Receives $3.0 Million Milestone Payment from GlaxoSmithKline
5. GlaxoSmithKline and Theravance Announce Start of Large Phase 2B ICS and LABA Studies for Asthma in the Horizon Program
6. Paul Capital Healthcare Purchases Additional Royalty Interest in GlaxoSmithKlines Rotarix(R)
7. GlaxoSmithKline Reports Further Progress of Oncology Portfolio
8. GlaxoSmithKline Announces New Drug Application and Phase III Results for Rezonic(TM)/Zunrisa(TM) (Casopitant)
9. GlaxoSmithKline Collaborates with National Cancer Institute to Make Large Body of Cancer Cell Genomic Data Available to All Cancer Researchers
10. GlaxoSmithKline Responds to FDA on CERVARIX(R) and Plans to Submit Final Study Data for Approval
11. Genmab and GlaxoSmithKline Announce Positive Top-Line Results in Ofatumumab Chronic Lymphocytic Leukemia Pivotal Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... NEW YORK , Jan. 16, 2017 /PRNewswire/ ... global peripherally inserted central catheters market for the ... is to offer updates and information related to ... catheters market. This comprehensive market study demonstrates the ... current environment and future status of the global ...
(Date:1/16/2017)... , Jan. 16, 2017 The global pacemaker ... 2025, according to a new report by Grand View ... with the availability of medical coverage is a key ... addition, technological enhancements in these devices are supporting the ... Diseases (CVDs) is a high-impact growth rendering driver for ...
(Date:1/16/2017)... HOUSTON , Jan. 16, 2017 ... of Potts Law Firm, was recently appointed Liaison Counsel ... Proceedings (JCCP) for all Xarelto cases. In this role, ... plaintiff parties and will actively assist the Court and ... with Milstein Adelman Jackson Fairchild & ...
Breaking Medicine Technology:
(Date:1/15/2017)... Cary, NC (PRWEB) , ... January 15, 2017 ... ... to announce that Albertsons Companies has achieved accreditation for its specialty care services. ... accreditation and its own in-house specialty care service for pharmacy patients. , Accreditation ...
(Date:1/15/2017)... ... 14, 2017 , ... Wondering where to go this Valentine's Day? Well, there ... for a romantic, lobster feast in the comfort of your own home. Lobster Gram ... dinners will be featured until February 15th, 2017. , Romantic Dinner one is ...
(Date:1/14/2017)... ... January 14, 2017 , ... Healthy living brand Moody ... activated charcoal products. With more and more people opting to go organic in ... how they cater to specific needs. , Moody Zook focused particularly on their ...
(Date:1/14/2017)... ... 14, 2017 , ... "TransFreeze Volume 3 is a self animating masking transition which allows users ... Pro X," said Christina Austin - CEO of Pixel Film Studios. , TransFreeze Volume ... from one clip to the next. , To use “Cut-Out First” presets, choose ...
(Date:1/13/2017)... (PRWEB) , ... January 13, 2017 , ... A January ... top five procedures for 2017 according to the publication, with an emphasis on some ... Payam Jarrah-Nejad, M.D., F.I.C.S., F.A.C.S., who is known more casually to his patients and ...
Breaking Medicine News(10 mins):